Subscribe
handshake-1-1
miodrag ignjatovic / iStockphoto.com
3 January 2019Americas

Bristol-Myers Squibb to acquire Celgene in $74bn deal

American pharmaceutical company Bristol-Myers Squibb (BMS) has announced it is purchasing drug manufacturer Celgene in a $74 billion deal.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Celgene sues Dr Reddy’s over Pomalyst generic
11 February 2021   Celgene has filed a lawsuit against Indian drugs manufacturer Dr Reddy’s Laboratories to halt its plan to produce and market generic versions of Pomalyst—Celgene’s multiple myeloma treatment.
Americas
BMS and Dr Reddy’s settle Revlimid suit with generics licence
22 September 2020   Bristol Myers Squibb and Celgene have settled their patent litigation with Dr Reddy’s over a generic version of cancer drug Revlimid.
Americas
BMS to acquire Forbius in oncology expansion
27 August 2020   Bristol Myers Squibb has announced a deal to acquire protein engineering company Forbius, including its portfolio of protein inhibitors.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Big Pharma
Celgene sues Dr Reddy’s over Pomalyst generic
11 February 2021   Celgene has filed a lawsuit against Indian drugs manufacturer Dr Reddy’s Laboratories to halt its plan to produce and market generic versions of Pomalyst—Celgene’s multiple myeloma treatment.
Americas
BMS and Dr Reddy’s settle Revlimid suit with generics licence
22 September 2020   Bristol Myers Squibb and Celgene have settled their patent litigation with Dr Reddy’s over a generic version of cancer drug Revlimid.
Americas
BMS to acquire Forbius in oncology expansion
27 August 2020   Bristol Myers Squibb has announced a deal to acquire protein engineering company Forbius, including its portfolio of protein inhibitors.

More on this story

Big Pharma
Celgene sues Dr Reddy’s over Pomalyst generic
11 February 2021   Celgene has filed a lawsuit against Indian drugs manufacturer Dr Reddy’s Laboratories to halt its plan to produce and market generic versions of Pomalyst—Celgene’s multiple myeloma treatment.
Americas
BMS and Dr Reddy’s settle Revlimid suit with generics licence
22 September 2020   Bristol Myers Squibb and Celgene have settled their patent litigation with Dr Reddy’s over a generic version of cancer drug Revlimid.
Americas
BMS to acquire Forbius in oncology expansion
27 August 2020   Bristol Myers Squibb has announced a deal to acquire protein engineering company Forbius, including its portfolio of protein inhibitors.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB